ALTRIA GROUP INC

Altria’s latest move: suing the FDA, boosting its 61st dividend in 57 years, and ramping up CapEx—an update on how the tobacco giant balances regulation and shareholder value.

Explore why Altria Group’s resilient tobacco brand delivers strong returns – a 57.9% 3‑year gain, solid P/E, and defensive dividend strategy amid industry decline.

Altria Group’s shares climb amid FDA’s foreign‑tobacco curbs, showing robust cash flow, steady dividends and resilience in a volatile market.

Altria’s dividend boost masks a shrinking cigarette core; investors face high yields but growing risk as ETFs pull back and diversification stalls.

Altria Group Inc’s profits rise while cigarette sales drop—investors weigh a costly smoke‑free shift against a solid 6% dividend and mixed market sentiment.

Altria’s 7.5% dividend rise keeps it a top pick for yield‑seeking investors, even as cigarette sales wane and regulation tightens—learn why the stock stays attractive.

Altria’s Q3 earnings show higher EPS but weaker sales, leading to a sharp share dip and UBS downgrades while the company lifts 2025 EPS guidance and boosts a $2bn buy‑back.

Altria Group Inc. will host a webcast on October 16, 2025, to present its third-quarter and nine-month earnings, providing insight into the company’s financial performance, guidance, and strategic initiatives.

Altria Group Inc. is undergoing a routine board transition with the retirement of George Muñoz, but its dividend policy and financial fundamentals remain unchanged, making it an attractive option for income-seeking investors.

Altria Group Inc. has reported strong Q2 earnings, exceeding expectations with a non-GAAP EPS of $1.44 and revenue of $6.1 billion.